Table 3. Risk estimates summary of the association of neutrophil-to-lymphocyte ratio with progression-free and overall survival of ovarian cancer patients.
| Progression free survival | Overall survival | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of | HR | 95% | I2 (%) | Ph† | Ph‡ | No. of | HR | 95% | I2 (%) | Ph† | Ph‡ | |
| Study | CI | Study | CI | |||||||||
| Overall | 7 | 1.80 | 1.22–2.65 | 79.1 | < 0.01 | 10 | 1.72 | 1.18–2.51 | 73.5 | < 0.01 | ||
| Subgroup analyses | ||||||||||||
| Number of cases | 0.53 | 0.41 | ||||||||||
| ≥ 150 | 4 | 1.61 | 1.14–2.27 | 74.4 | < 0.01 | 6 | 1.48 | 1.04–2.12 | 70.0 | < 0.01 | ||
| < 150 | 3 | 2.47 | 0.63–9.672 | 86.5 | < 0.01 | 4 | 2.94 | 0.87–9.96 | 80.1 | < 0.01 | ||
| Geographic location | N/A | 0.35 | ||||||||||
| Asia | 7 | 1.80 | 1.22–2.65 | 79.1 | < 0.01 | 9 | 1.91 | 1.27–2.86 | 72.8 | < 0.01 | ||
| Europe | 0 | N/A | N/A | N/A | N/A | 1 | 0.87 | 0.52–1.44 | N/A | N/A | ||
| Cut-off method | 0.75 | 0.37 | ||||||||||
| ROC | 4 | 1.98 | 1.41–2.78 | 42.4 | 0.16 | 6 | 2.03 | 1.44–2.88 | 32.9 | 0.19 | ||
| Non-ROC | 3 | 1.70 | 0.64–4.46 | 86.0 | < 0.01 | 4 | 1.36 | 0.71–2.59 | 80.0 | < 0.01 | ||
| Adjustment for potential confounders and risk factors | ||||||||||||
| Age at diagnosis/surgery | 0.31 | 0.39 | ||||||||||
| Yes | 3 | 2.85 | 0.95–8.55 | 87.5 | < 0.01 | 6 | 2.28 | 1.17–4.44 | 77.9 | < 0.01 | ||
| No | 4 | 1.51 | 0.96–2.39 | 69.0 | 0.02 | 4 | 1.52 | 0.97–2.39 | 62.6 | 0.05 | ||
| FIGO stage | 0.87 | 0.73 | ||||||||||
| Yes | 4 | 1.97 | 0.88–4.43 | 46.4 | 0.16 | 5 | 2.09 | 0.98–4.48 | 78.6 | < 0.01 | ||
| No | 3 | 1.84 | 1.29–2.63 | 84.0 | < 0.01 | 5 | 1.60 | 0.99–2.59 | 69.7 | 0.01 | ||
| Tumor grade | 0.09 | 0.44 | ||||||||||
| Yes | 1 | 6.87 | 2.64–17.91 | N/A | N/A | 3 | 3.52 | 0.57–21.94 | 87.8 | < 0.01 | ||
| No | 6 | 1.57 | 1.11–2.21 | 73.2 | < 0.01 | 7 | 1.57 | 1.10–2.22 | 65.6 | < 0.01 | ||
| Performance status | 0.09 | 0.02 | ||||||||||
| Yes | 1 | 6.87 | 2.64–17.91 | N/A | N/A | 2 | 9.33 | 3.38–25.77 | 0 | 0.72 | ||
| No | 6 | 1.57 | 1.11–2.21 | 73.2 | < 0.01 | 8 | 1.44 | 1.04–1.99 | 66.2 | < 0.01 | ||
| CA-125 level | 0.04 | 0.02 | ||||||||||
| Yes | 2 | 4.70 | 2.34–9.42 | 12.8 | 0.28 | 4 | 5.18 | 2.01–13.38 | 47.3 | 0.13 | ||
| No | 4 | 1.45 | 1.03–2.05 | 73.4 | < 0.01 | 6 | 1.32 | 0.94–1.84 | 69.2 | < 0.01 | ||
| SIR markers | 0.53 | 0.90 | ||||||||||
| Yes | 3 | 2.47 | 0.63–9.672 | 86.5 | < 0.01 | 5 | 2.05 | 0.83–5.04 | 80.4 | < 0.01 | ||
| No | 4 | 1.61 | 1.14–2.27 | 74.4 | < 0.01 | 5 | 1.66 | 1.12–2.46 | 69.9 | 0.01 | ||
Abbreviations: CA-125, carbohydrate antigen-125; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; N/A, not available; ROC, receiver-operating curve; SIR, systemic inflammatory response.
†P-value for heterogeneity within each subgroup.
‡P-value for heterogeneity between subgroups with meta-regression analysis.